



Purpose: different strategies have been developed to
reduce blood loss in total knee arthroplasty (tKA).
the efficacy of  both systemic and local tranexamic
acid (tXA) administration is demonstrated in the lite-
rature. the aim of  the present study was to compare
the efficacy of  systemic, local and combined (systemic
+ local) administration of  tXA in reducing blood loss
after tKA. 
Methods: we enrolled all patients submitted to a pri-
mary tKA in our department between november
2014 and August 2015. they were divided into three
groups corresponding to the method of  tXA admini-
stration used: intravenous (iV), intra-articular (iA),
and a combination of  the two. Demographic data, as
well as preoperative hemoglobin and platelet levels,
were collected. the primary outcome was the maxi-
mum hemoglobin loss, while the secondary outcomes
were the amount of  blood in the drain (cc/hour) and
the rate of  transfusions; postoperative pain was also
assessed. student’s t-test or a χ2 test was used to eval-
uate between-group differences, using p<0.05 as the
cut-off  for statistically significant differences.
Results: the sample comprised 34 patients: iV, 10
cases; iA, 15 cases, and combined (iV + iA), 9 cases.
the average age of  the patients was 71.1+6.4 years.
no significant differences in the outcome measures
were found between the groups, with the exception of
a significantly lower maximum hemoglobin loss in the
combined versus the iV group (p=0.02). there were no
differences between the groups in the amount of
blood in the drain or the rate of  transfusions. 
Conclusions: the data from this preliminary study, as
well as data from the literature, confirm that tXA
administration is safe and effective in reducing total
blood loss in tKA, and no administration protocol
seems to be superior to the others.
Level of  evidence: Level ii, prospective comparative
study.
Keywords: tranexamic acid, knee, arthroplasty, bleed-
ing, blood loss.
Introduction
Perioperative bleeding remains one of  the main con-
cerns in elective total knee arthroplasty (tKA), with
blood loss ranging between 800 ml and 1800 ml (1-3).
Fibrinolysis induced by surgical trauma, which may be
increased by using a tourniquet, reduces the risk of
venous thromboembolism, but at the same time favors
postoperative blood loss (4, 5). Different methods to
reduce perioperative blood loss have been studied,
such as perioperative blood donation, perioperative red
cell salvage, deliberate hypotension, and use of  recom-
binant human erythropoietin. Furthermore, periopera-
tive transfusions add to the costs of  the treatment and
the risks (of  infection, allergic reaction and disease
transmission, for example) to the patient (6, 7). 
in recent years, pharmacological approaches have
become more popular. As hyperfibrinolysis is consid-
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ered the major cause of  postoperative bleeding after
tKA surgery, antifibrinolytic drugs have been pro-
posed, including aprotin, aminocaproic acid, and
tranexamic acid (tXA).
tXA is a fibrinolysis inhibitor, which prevents clot
lysis by blocking the proteolytic activity of  plasmino-
gen activators (8). since the first report by Benoni et
al. (9), different studies have been published on the
efficacy of  tXA in reducing perioperative blood loss
in total joint arthroplasty. 
theoretically, intravenous (iV) administration of
tXA increases the risk of  thrombotic events.
Furthermore, some cases of  allergic reaction to tXA
have also been reported. For these reasons, some
Authors consider tXA contraindicated in patients
with a history of  allergy, arterial or venous thrombo-
sis, an intrinsic risk of  thrombosis or thromboem-
bolism, acute renal failure, subarachnoid hemorrhage,
or a history of  epilepsy (10). other studies have
demonstrated that the supposed increased risk of
thrombotic events can be avoided by the usual post-
operative prophylactic regimens against deep vein
thrombosis (DVt), such as aspirin, warfarin, low-mol-
ecular-weight heparin (LMWH) (11-14), and even fac-
tor Xa inhibitor (15).
Different Authors have proposed topical iA adminis-
tration of  tXA before wound closure in order to
reduce the possible complications related to the risk of
thrombotic events (3, 16, 17). Another route for local
administration is through the drain, with or without
drain clamping (18). some studies also showed the
efficacy of  orally administered tXA in patients under-
going primary tKA compared with controls (19, 20).
in the literature, there is considerable variability in the
timing of  administration (which may be preoperative,
intraoperative or postoperative, or a combination of
these), as well as in the amount of  tXA administered.
Reported iV tXA doses range from 10 to 20 mg/kg
although, in several studies, a 1 g dose (ranging from
500 mg to 3 g) was used as standard. in continuous
infusion, doses range from 2 mg/kg/h for 20 hours to
10 mg/kg/h for 3 hours. iV tXA has been used as
single dose bolus or as continuous infusion (for 2-3
hours) (21-23). 
For topical administration, doses of  tXA range from
250 mg to 3 g, diluted in 75 to 250 ml of  saline solu-
tion. tXA has also been shown to be effective admin-
istered with other topical medications, like povidone-
iodine solution (3 g of  topical tXA in povidone-
iodine solution) (24).
the aim of  the present study was to compare the effi-
cacy of  systemic, local and combined administration
of  tXA in reducing blood loss after tKA. the
hypothesis of  the study was that there is no significant
difference between the three treatment protocols.
Methods
All the patients who underwent a primary tKA in our
department between november 2014 and August
2015 were enrolled in this study. they were divided
into three groups, corresponding to the tXA admin-
istration protocol used: group 1, iV: 10 mg/kg of
tXA in 50 ml of  saline solution administered over a
time of  10 minutes during induction and 3 hours later;
group 2, iA: washing with 2 g of  tXA in 20 ml of
sterile saline for 2 minutes after placement of  the final
components; and group 3, a combination of  the two
methods (iV+iA). Patients with contraindications to
iV administration (a medical history of  DVt or pul-
monary thromboembolism, acute myocardial infarc-
tion, heart failure, heart valve stenosis, ischemic
stroke, coagulopathy, allergy to tXA, severe liver or
kidney disease) were included in the iA protocol. All
the patients received a dose of  LMWH 12 hours
before surgery, and LMWH treatment was continued
postoperatively for 30 days. 
All the surgeries were performed using a standard
medial parapatellar approach, with cemented compo-
nents and using a tourniquet during the cementation
phase. in all the patients an iA drain (without suction)
was subsequently positioned and kept in place for 24
hours. Postoperatively the knee was positioned in 50°
to 70° of  flexion for 6 hours (25, 26). Knee mobiliza-
tion and weight bearing were allowed between day one
and day two postoperatively. Continuous passive
motion was started on postoperative day one. 
Demographic data, as well as preoperative hemoglo-
bin and platelet levels, were collected. Patients were
interviewed about their pain preoperatively, the day
after surgery, and on the fifth postoperative day. the
numeric pain rating scale (nRs) was used for this pur-
pose. Maximum hemoglobin loss (calculated as the
difference between the preoperative and lowest post-
operative hemoglobin level) was taken as the primary
tranexamic acid in tKa
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outcome measure for evaluating the efficacy of  tXA.
the secondary outcomes were the amount of  blood
in the drain (cc/hour) and the rate of  transfusions.
the hemoglobin cut-off  value for transfusion was 8
g/dl in symptomatic patients. However, patients with
cardiac disease could also undergo transfusion also
even in the presence of  high hemoglobin levels. 
Complications, such as postoperative fever (>38.5°),
bruising, wound dehiscence, hematoma, DVt, throm-
botic events and infections were recorded. 
student’s t-test or a χ2 test was used to evaluate the dif-
ferences between the groups, using p<0.05 as the cut-
off  for statistically significant differences.
Results
the study population comprised 34 patients with a
mean age of  71.1 years (sD 6.45; range 59-83), and a
mean BMi of  29.17 kg/m2 (sD 4.82, range 16.8 to
38.9); 58.8% (20 cases) were women and 41.2% (14
cases) were men.
in accordance with the abovementioned inclusion and
exclusion criteria, the patients were divided into three
groups corresponding to the method of  tXA admin-
istration used: iV, 10 cases; iA, 15 cases; combined, 9
cases. the three groups were not homogenous. in par-
ticular, the iV group patients were significantly
younger than those in the iA group (p=0.04), and the
combined group had a significantly lower preoperative
hemoglobin level compared with the iV group
(p=0.04). there were no differences in gender distri-
bution or platelet levels between the groups. the max-
imum hemoglobin loss (preoperative Hb – lowest
postoperative Hb level) was 4.3 g/dl (sD 1.5; range
2.1 to 7 g/dl) in the iV group, 3.6 g/dl (sD 1.2; range
1.6 to 5.4 g/dl) for the iA group, and 2.8 g/dl (sD 0.9;
range 1.4 to 4.3 g/dl) in the combined group. in this
regard, the analysis of  the data revealed no statistically
significant difference between the iV and iA groups
(p=0.25) or between the iA group and the combined
group (p=0.13). However, the combined group
showed a significantly lower maximum hemoglobin
loss compared with the iV group (p=0.02) (Tab. 1).
the amount of  blood found in the drain was 4.9 cc/h
(sD 5.3; range 0.4 to 15.2) in the iV group, 10.7 cc/h
(sD 12.2, range from 0.4 to 38.9) in the iA group, and
11.4 cc/h (sD 8.1, range 0.4 to 26.1) in the combined
group. the rate of  blood transfusions was: 10% (1
case) in the iV group, 40% (6 cases) in the iA group
and 22.2% (2 cases) in the combined group. there
were no statistically significant differences in these
secondary outcomes (blood in drain and transfusion
rate) between the three groups (Tab. 1). the average
preoperative nRs score was statistically higher in the
combined group (p=0.03) compared to the iV group,
but it was similar to the score recorded in the iA
group. However, there were no differences in nRs
score on the first or fifth postoperative day between
the iV and the combined group. the only significant
difference in nRs values was found on the fifth post-
operative day, when comparing the iA vs combined
groups (p=0.006) (Tab. 1). 
no complications occurred in any of  the included
patients. in particular, no DVt or other thrombotic
events were detected. 
Discussion
this study demonstrated that tXA is effective in
reducing total blood loss, transfusion rate and blood
in the drain, without increasing the rate of  complica-
tions. 
As different Authors have demonstrated, iV adminis-
tration of  tXA in tKA is safe and effective, both
when given as a single dose and when adding a second
or third dose intraoperatively or postoperatively (27-
29). in particular, Levine et al., in a randomized con-
trolled trial, demonstrated that a standard dose of  1 g
iV can be used with the same efficacy as weighted
doses (20 mg/kg) (30). iwai et al. demonstrated that a
double iV dose of  tXA produced a further reduction
of  postoperative blood loss in tKA compared to a
single administration (31), especially if  the doses were
given preoperatively and intraoperatively. similarly,
Maniar et al., also in a randomized controlled trial,
demonstrated that a three-dose regimen (adding a
postoperative dose) may be even more effective (32).
Most of  the studies confirmed the efficacy of  differ-
ent doses of  iV tXA in reducing transfusion rates
and total blood loss (27, 33-38) (Tabs. 2, 3).
However, some Authors reported a potential in creased
risk of  thrombotic events and some cases of  allergic
reaction (10). For these reasons, the iA route of  tXA
administration was proposed. Different Authors have
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confirmed the efficacy of  iA administration, albeit
proposing different doses and different methods of
topical administration (washing or through the drain)
(24, 38-42). in particular, Georgiadis et al. randomized
patients to two groups receiving either 2 g of  tXA in
75 ml of  saline or a placebo solution intraoperatively.
the Authors demonstrated a significant reduction of
total blood loss in the tXA group, without the poten-
tial complications related to iV administration (39).
Patel et al., in a study of  89 patients who underwent a
primary tKA, demonstrated that iV administration of
10 mg/kg of  tXA and iA administration of  2 g tXA
were equally effective in reducing blood loss (16).
similarly, various recent studies have demonstrated the
efficacy of  iA tXA administration in reducing blood
loss after tKA (Tabs. 2, 3) (24, 29, 40-47). 
Furthermore,  recent meta-analyses showed no differ-
ence between topical and iV tXA administration (44,
48-55), even though some Authors reported conflict-
ing results (43, 46, 47, 56).
there are only few studies in the literature that have
examined the association of  an iV protocol with a
local one in patients undergoing tKA. Jain et al.
showed better results in terms of  mean total blood
loss, transfusion rate and hemoglobin drop, using a
combined protocol compared to only iV administra-
tion (57). similarly, Lin et al., in a study of  120
patients, demonstrated greater reductions in blood
loss, hemoglobin drop, total drain amount and trans-
fusion rate using a combined protocol compared to
iA administration alone (28). Karaaslan et al. evaluat-
ed the efficacy of  an association of  three different
methods of  tXA administration in bilateral tKA: a
bolus dose of  15 mg/kg 10 min before the inflation
of  the tourniquet, followed by iA administration of  3
g 10 min before the deflation of  the tourniquet, asso-
ciated with an iV infusion of  10 mg/kg/h for 3h fol-
lowing the surgery. the Authors concluded that this
method of  tXA administration was effective in
reducing total blood loss in bilateral tKA (34). Huang
et al. compared the results of  iV tXA administration
(3 g) with those of  a combined approach (1.5 g iA and
1.5 g iV). the Authors concluded that the two
approaches were similarly effective in reducing trans-
fusion rate and total blood loss, but the combined
protocol gave better results in terms of  maximum
decline of  hemoglobin, drainage volume, postopera-
tive knee pain, knee swelling, length of  hospital stays
and short-term satisfaction (29).
in view of  the established efficacy of  tXA in tKA
irrespective of  the method of  administration, we con-
ducted a preliminary prospective cohort study in 34
patients, divided into iV administration, iA adminis-
tration, and a combination of  the two. the aim of  this
study was to evaluate whether one method of  admin-
istration was more effective than the others. the
results of  the study showed no differences in hemo-
globin loss, amount of  blood in the drain, and rate of
Table 1. Results of  the study.
                                  Maximum Hb         Lowest Hb     Blood in drain     Transfusion                                         NRS                   
                                     loss (g/dl)              (g/dl)             (cc/hour)           rate (%)                
                                                                                                                                                           Preoperative           1st  postop.        5th postop. 
                                                                                                                                                                                           day                    day
                                     
IV GROUP              4.3 ± 1.55              10.1±1.54       4.94±5.33           10%                    8.7 ±0.67              5.1 ±2.68         3.4 ±2.59
IA GROUP              3.64 ± 1.24            9.3±0.94         10.67±12.25        40%                    9 ±0.76                 3.8 ±1.97         1.73 ±1.83
p-value                       0.25                        0.14                0.18                    0.10                    0.32                      0.18                  0.07
IV GROUP               4.3 ± 1.55              10.1±1.54       4.94±5.33           10%                    8.7 ±0.67              5.1 ±2.68         3.4 ±2.59
IV+IA GROUP       2.8 ± 0.92              9.54±1.53       11.43±8.17         22.2%                 9.4 ±0.73              4.4 ±1.42         3.55 ±2.79
p-value                       *0.02                      0.48                0.06                    0.47                    *0.03                     0.52                  0.89
IA GROUP               3.64 ± 1.24            9.3±0.94         10.67±12.25        40%                    9 ±0.76                 3.8 ±1.97         1.73 ±1.83
IV+IA GROUP        2.8 ± 0.92              9.54±1.53       11.43±8.17         22.2%                 9.4 ±0.73              4.4 ±1.42         3.55 ±2.79
p-value                       0.13                        0.63                0.88                    0.37                    0.17                      0.4                   *0.006
* p statistically significant (<0.05)
Abbreviations: tXA = tranexamic acid; iV =  intravenous; iA = intra-articular; Hb =  hemoglobin; nRs = numerical Rating scale score.
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Table 2. summary of  meta-analyses on the efficacy of  tranexamic acid in total knee arthroplasty. 
AUTHOR           YEAR    PROTOCOL    STUDIES                 OUTCOMES    RESULTS
                                                                                                         EVALUATED   
Alshryda s. et al.  2011        iV or topical      19 RCts                     Blood loss,
(44)                                      or oral                 (18 involving             transfusion
                                                                      iV administration,     rate
                                                                      1 iA administration, 
                                                                      and 1 oral 
                                                                      administration)                                     
Zhang H. et al.     2012        iV                       15 RCts                     Blood loss, 
(48)                                                                                                   transfusion rate    
Panteli M. et al.    2013       topical               7 (4 RCts, 1 PCs,     Blood loss,
(49)                                                                 2 quasi-RCts)            hemoglobin drop,  
                                                                                                         transfusion rate 
Wang H. et al.      2014       iV or topical      6 (5 RCts, 1 PCs)     total blood loss, 
(50)                                                                                                   Hemoglobin drop,
                                                                                                         drain output, 
                                                                                                         transfusion rate    
Alshryda s. et al.  2014        topical                14 RCts                    transfusion rate
(51)                                                                 (11 knee replacement,
                                                                      1 hip replacement, 
                                                                      1 both)                      
                             
Kim tK. et al.      2014        iV or topical       28 RCts                    Blood loss, drain
(52)                                                                 (22 involving iV        output, transfusion
                                                                      administration;          rate
                                                                      6 iA administration)                              
                             
Wu Q. et al.          2015        iV or topical       34 RCts                     Blood loss 
(53)                                                                                                   (intra operative 
                                                                                                         and postoperative), 
                                                                                                         hemoglobin drop, 
                                                                                                         safety 
Reduction in blood loss (MD 591 ml; 95% Ci
536 to 647, p<0.001; heterogeneity i2 = 78%),
reduction in transfusion rate (RR 2.56, 95% Ci
2.1 to 3.1, p<0.001; heterogeneity i2 = 75%)
Reduction in blood loss (MD  487ml, 95% Ci
-629 to -344), reduction in transfusion rate (risk
difference - 0.4, p<0.00001)
Reduction in total blood loss (MD = - 220.08
ml, p<0.00001, 95% Ci = -279.54 ml to -
160.63 ml), maximum hemoglobin drop (MD =
-0.94 gr/dl, 95% Ci = -1.24 gr/dl to  -0.65
gr/dl, p< 0.00001); lower risk of  transfusions
(RR = 0.47, p=0.01, 95% Ci = 0.26 to 0.84)
no differences as regards total blood loss (MD
–14.36, 95% Ci  – 92.02 to 63.30), hemoglobin
loss (MD 0.43, 95% Ci – 0.25 to 1,11), total
drain output (MD 21.91, 95% Ci – 85.01 to
128.82), transfusion rate (RR 1.02, 95% Ci 0.70
to 1.9)
Reduction in transfusion rate (RR 4.51; 95%
Ci: 3.02 to 6.72; p<0.001; heterogeneity i2=
0%)                        
Reduction in blood loss (range = 191 ml to 942
ml, 14 % to 64 % reduction), drain output
(range = 65 ml, 8% reduction to 785 ml, 66%
reduction), hemoglobin drop (range = 0.4 g/dl,
to 2.8 g/dl, 12% to 70% reduction). Variability
in transfusion rate and conflicting results in
comparison between iV and topical
Reduction in total blood loss [iA (sMD -0.86,
95%Ci -1.14 to  -0.59, p=0.000) iV (sMD = -
1.01, 95%Ci -1.43 to -0.60; p=0.00)], in
postoperative blood loss [iA (sMD = -1.32, 95
% Ci -2.08 to -0.55; p=0.001) iV (sMD = -
1.11, 95%Ci -1.61 to -0.61; p=0.000)]. no
reduction in intraoperative blood loss.
Reduction in hemoglobin drop [iA (sMD = 
-0.65, 95%Ci -0.96 to -0.35; p=0.000) iV 
(sMD = -0.85, 95 Ci -1.26 to -0.44; p=0.000)].
no complications  




transfusions between the combined protocol and top-
ical administration alone. on the contrary, less hemo-
globin loss was found in the combined group com-
pared with the iV only administration group (p=0.02).
However, it must be emphasized that patients in the
iV group had significantly higher preoperative hemo-
globin values than those of  the combined  (iV + iA
group), and this can be considered a bias. With regard
to the secondary outcomes (blood in drain and trans-
fusion rate), no differences were detected between the
three groups. in conclusion, although the combined
protocol was found to be superior to the iV protocol,
both are comparable to the iA protocol in terms of
efficacy. 
this study has some limitations. First, it is not a ran-
domized controlled trial and the groups are not
homogeneous, so there are potential biases. in partic-
ular, there is an indication bias, since all the patients
with a potential contraindication to iV tXA adminis-
tration (i.e. previous thrombotic events, anti-coagula-
tion therapy) were allocated to the iA group. For this
reason, the iA group presented a higher risk of  bleed-
ing, compared with the others. However the iA proto-
col, even though it was applied in patients with more
comorbidities and a higher risk of  bleeding, neverthe-
less showed equivalent efficacy to the other protocols.
therefore, these preliminary results confirm the effi-
cacy of  iA tXA administration, and represent a stim-
ulus, for the Authors, to plan a randomized control
trial. A further limitation is the absence of  a control
group. that said, the efficacy of  tXA, whether
administered topically or systemically, has previously
been extensively described and is widely accepted.
Finally, the power of  the study was certainly reduced
by the small size of  the sample. However, these are
preliminary data, and the study will be continued,
introducing a randomization procedure, to confirm
the significance of  the results obtained.
the above-described preliminary experience with tXA
in tKA is in line with what is reported in the literature.
no significant differences in maximum loss of  hemo-
globin were observed between the different treatment
Table 2. summary of  meta-analyses on the efficacy of  tranexamic acid in total knee arthroplasty. 
AUTHOR           YEAR    PROTOCOL    STUDIES                 OUTCOMES    RESULTS
                                                                                                         EVALUATED   
shemshaki H.       2015       iV or topical      31 RCts                    Blood loss, 
et al. (54)                                                                                           transfusion rate, 
                                                                                                         comparison 
                                                                                                         between iA 
                                                                                                         and iV 
Yue C. et al. (55)   2015        topical                12 RCts                     Blood loss, 
                                                                                                         transfusion rate, 
                                                                                                         comparison of  
                                                                                                         dosages                
Abbreviations: tXA = tranexamic acid; iV =  intravenous; iA =  intra-articular; Ci = confidence interval; MD = mean difference; sMD = standardized
mean difference; RR =  risk ratio; RCt = randomized controlled trial; Quasi-RCt = quasi-randomized controlled trial; PCs = prospective cohort study.
Reduction in blood loss [iV (MD = 392.72
ml, 95% Ci 528.12 to -257.33; p<0.001) iA
(MD = 282.44 ml, 95%Ci 574.73 to 9.85;
p<0.001)], reduction in transfusion rate [iV
(RR 0.44; 95% Ci 0.33 to 0.59; p<0.001) iA
(RR 0.27; 95% Ci 0.16–0.45; p<0.001)]. no
differences between iV or iA administration
(blood loss p=0.50; transfusion rate p=0.30)
Reduction in blood loss (MD -280.65 ml, 95%
Ci, -376.43 to -184.88; p<0.00001); reduction
in transfusion rate (risk ratio=0.26; 95% Ci,.
0.19 to 0.37; p<0.00001; heterogeneity
i2=34%); reduction in drainage output  (MD -
194.59 ml, 95% Ci, -315.86 to -73.32;
p<0.002; heterogeneity i2=63%). High
concentration is better than low concentration
(total blood loss: mean reduction of  335.79
ml in high concentration group versus 213.47
ml in low concentration group; transfusion
rate: risk ratio=0.23 in high concentration
group versus 0,37 in low concentration group)
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Table 3. summary of  randomized controlled trials on the efficacy of  tranexamic acid in total knee arthroplasty. 
AUTHOR                                  YEAR                                    NUMBER OF PATIENTS        PROTOCOL                                                                                              O                                                          R
Jain nP. et al. (57)                                  2016                                        119                                                  iV versus combined                                                                                      B                                                                   C             
                                                                                                                                                                                                                                                                                                                                                                                             u           
                                                                                                                                                                                                                                                                                                                                                                                             (     
Aguilera X. et al. (43)                   2015                                        150                                                  iV (2 g) or topical (1g) versus placebo                                                         B                              B           
                                                                                                                                                                                                                                                                                                                                                                                             n        
shen PF. et al. (33)                       2015                                        92                                                    iV 15 mg/kg in 100 ml saline, 10 minutes                                                  i                 s          
                                                                                                                                                            before tourniquet release                                                                              d                  (          
                                                                                                                                                                                                                                                                                 v                t           
                                                                                                                                                                                                                                                                                 a                   (  
Hourlier. et al. (27)                       2015                                        106                                                  iV single dose 30 mg/kg intraoperative                                                      B                                                                                  A             
                                                                                                                                                            versus 10 mg/kg + 2 mg/kg as continuous                                                                                                                                                             (
                                                                                                                                                            infusion 2 h later for 20 h                                                                                                                                                                                       
Karaaslan F. et al. (34)                 2015                                        81 undergoing bilateral tKA          iV 15 mg/kg 10 min before inflation of  the                                              V                      D         
                                                                                                                                                            tourniquet (and continued at 10 mg/kg for 3 h)                                         h                       w         
                                                                                                                                                            + 3 g iA 10 min before deflation of  the tourniquet                                   t                                                                                           
Carvalho LH Jr. et al. (24)           2015                                        125                                                  iA 1.5 and 3.0 g in povidone-iodine solution                                              M                       H           
                                                                                                                                                                                                                                                                                                                                                                                             (         
Lin sY. et al. (28)                        2015                                        120                                                  Combined versus iA versus placebo                                                                M                C          
                                                                                                                                                            drop; total drain amount                                                                                                                                                                                         c          
                                                                                                                                                                                                                                                                                                                                                                                             a    
Gomez-Barrena E. et al. (46)       2014                                        78                                                    iA 3 g in 100 ml saline and two 15 mg/kg                                                 D                                 t          
                                                                                                                                                            iV doses (before tourniquet release and after                                                                                                                                                        w             
                                                                                                                                                            three hours)                                                                                                                                                                                                             4          
Yang Y. et al. (45)                         2015                                        80                                                    iA 500 mg in 20 ml saline                                                                           B                                                         L             
                                                                                                                                                                                                                                                                                                                                                                                             c    
Huang Z. et al. (29)                      2014                                        184                                                  iV 3 g versus combined iV 1.5 g + topical 1.5 g                                          t                                                  C        
                                                                                                                                                                                                                                                                                                                                                                                             h        
                                                                                                                                                                                                                                                                                                                                                                                             k            
                                                                                                                                                                                                                                                                                                                                                                                             d    
soni A. et al. (3)                           2014                                        40                                                    3 iV doses versus topical                                                                               B                                                                       n          
                                                                                                                                                                                                                                                                                                                                                                                             (
                                                    
Patel Jn. et al. (16)                       2014                                        89                                                    iV 10 mg/kg versus topical 2 g                                                                   H                             s           
                                                                                                                                                                                                                                                                                                                                                                                             i          
                                                                                                                                                                                                                                                                                                                                                                                             d     
                                                    
sarzaeem MM. et al. (56)                                                             200                                                  iV 1500 mg versus iA 3 g in 100 cc saline versus                                           H                                  A        
                                                                                                                                                            1.5 g injected through the drain versus placebo                                                                                                                                                      (          
                                                                                                                                                                                                                                                                                                                                                                                             d          
                                                                                                                                                                                                                                                                                                                                                                                             g           
                                                                                                                                                                                                                                                                                                                                                                                             d      
sa-ngasoongsong P. et al. (41)    2013                                        135                                                  iA 250 mg versus iA 500 mg (both injected                                                 H                                              t           
                                                                                                                                                            through the drain with a 2 h drain clamping)                                                                                                                                                          (     
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                                  Y                                     N           P                                                                                              OUTCOMES EVALUATED                                                        RESULTS
                                      2                                        1                                                   i                                                                                        Blood loss, transfusion rate                                                                Combined use of  iV and topical tXA provided better results than iV 
                                                                                                                                                                                                                                                                                                                                                                                             use alone: less total blood loss (p=0.001), lower transfusion rate 
                                                                                                                                                                                                                                                                                                                                                                                             (p=0.001), smaller hemoglobin drop (p=0.001).
                      2                                        1                                                   i                                                                Blood loss, transfusion rate, hidden blood loss, safety                       Both effective in reducing loss (p=0.001), reduction in transfusion rate; 
                                                                                                                                                                                                                                                                                                                                                                                             no differences between the two tXA groups (p=0.073)
                          2                                        9                                                     i                                                           intraoperative blood loss; postoperative drainage at 12 h; total        significant reduction in postoperative drainage amount at 12 h 
                                                                                                                                                            b                                                                                drain amount; hidden blood loss; total blood loss; transfusion         (p=0.000), total drain amount (p=0.000), hidden blood loss (p=0.001), 
                                                                                                                                                                                                                                                                                 volumes; number of  transfusions; postoperative hemoglobin          total blood loss (p=0.004), and postoperative D-dimer value at 24 h
                                                                                                                                                                                                                                                                                 at 1, 3, and 5 days; D-dimer; number of  lower limb ecchymose       (p=0.000). 
                         2                                        1                                                   i                                                            Blood loss, safety                                                                                A single bolus of  tXA 30 mg/kg is as effective as a continuous infusion
                                                                                                                                                            v                                                                                                                                                                    (p=0.68)
                                                                                                                                                            i                                                                                                                                                                                              
K                     2                                        8              i                                                       Volume of  drained blood 48 h postoperatively, decrease in             Drained blood (p=0.05), hemoglobin drop (p=0.05) and transfused units
                                                                                                                                                            t                                                  hemoglobin levels 12 h postoperatively, amount of  blood                were lower in the tXA group compared with controls
                                                                                                                                                            +                                             transfused                                                                                           
C                 2                                        1                                                   i                                                      Mean postoperative hemoglobin levels, blood loss, safety                 Higher mean hemoglobin level (p=0.001, p=0.003) and lower blood loss 
                                                                                                                                                                                                                                                                                                                                                                                             (p=0.07, p=0.09) in the tXA group compared with controls
                            2                                        1                                                   C                                                                  Mean total blood, transfusion rate; postoperative hemoglobin         Combining preoperative iV injection and topical administration of  tXA 
                                                                                                                                                            d                                                                                                                                                                                             can effectively reduce blood loss (p=0.001), total drain amount (p=0.001)
                                                                                                                                                                                                                                                                                                                                                                                             and transfusion rate (p=0.009).
          2                                        7                                                     i                                                            Drain blood loss at 24 and 48 hours, transfusion rate                       topical administration is as effective and safe as iV administration,
                                                                                                                                                            i                                                                                                                                                               with no differences in blood loss at 24 h (p=0.948), blood loss at
                                                                                                                                                            t                                                                                                                                                                                                               48h (p=0.837) or  transfusion rate (0% in both groups)
                            2                                        8                                                     i                                                                                  Blood loss, transfusion rate, safety                                                     Less total blood loss and lower transfusion rate in the tXA group 
                                                                                                                                                                                                                                                                                                                                                                                             compared with controls (p=0.05)
                         2                                        1                                                   i                                                     transfusion rate, total blood loss, safety                                            Combined administration obtains smaller maximum decline of  
                                                                                                                                                                                                                                                                                                                                                                                             hemoglobin p=0.031), smaller drain volume (p=0.011), less postoperative
                                                                                                                                                                                                                                                                                                                                                                                             knee pain, less knee swelling, shorter length of  hospital stays. no 
                                                                                                                                                                                                                                                                                                                                                                                             differences in transfusion rate
                              2                                        4                                                     3                                                                                  Blood loss, blood in drain                                                                  no differences in hemoglobin drop (p=0.38) and blood in drain
                                                                                                                                                                                                                                                                                                                                                                                             (p=0.48)
                                                    
P                           2                                        8                                                     i                                                                          Hemoglobin level,  total drain output, transfusion rate                     systemic and topical tXA administration found to be equally effective as
                                                                                                                                                                                                                                                                                                                                                                                             in terms of  hemoglobin drop (p=0.108), transfusion rate (p=0.342), total
                                                                                                                                                                                                                                                                                                                                                                                             drain output (p=0.339) and safety
                                                    
s                                                                 2                                                   i                                                     Hemoglobin drop, blood in drain, transfusion rate                           All administrations showed smaller hemoglobin drop versus controls
                                                                                                                                                            1                                                                                                                                                             (p=0.05); iV administration is more effective in reducing hemoglobin 
                                                                                                                                                                                                                                                                                                                                                                                             drop p=0.05) and transfused units (p=0.031) compared with other 
                                                                                                                                                                                                                                                                                                                                                                                             groups. Joint irrigation is better than drug administration through the 
                                                                                                                                                                                                                                                                                                                                                                                             drain for obtaining hemoglobin drop (p=0.001)
        2                                        1                                                   i                                                         Hemoglobin drop, transfusion rate, safety                                         the two protocols were equally effective in reducing total blood loss




groups, with the exception of  the finding of  a greater
value in the combined than in the iV one. However, as
mentioned, there are different confounding factors in
this study, and it will be necessary to increase the sam-
ple size and to randomize the patients in order to
increase its power. in conclusion, tXA administration
in tKA is safe and efficient in reducing total blood loss,
hemoglobin loss, blood in drain and transfusion rate.
intravenous tXA administration is reported to be relat-
ed to an increased thrombotic risk, but this assumption
is not completely confirmed by the literature. instead,
there is agreement regarding the comparable efficacy of
iA tXA administration, which is not associated with a
potential increased thrombotic risk. 
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